share_log

Arch Biopartners Arranges Non-Brokered Private Placement

Arch Biopartners Arranges Non-Brokered Private Placement

Arch Biopartners安排非經紀人定向增發
GlobeNewswire ·  07/30 04:52

TORONTO, July 29, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a non-brokered private placement offering of 400,000 common shares priced at $1.50 per common share (the "Common Shares") for gross proceeds of $600,000 CAD (the "Offering").

2024年7月29日(環球新swire)--Arch Biopartners Inc.(“Arch”或“公司”)(TSX Venture:ARCH和OTCQB:ACHFF)今日宣佈,其已安排400,000股普通股的非經紀定向增發,每股定價1.5加元(“普通股”),總收益爲600,000加元(“發行”)

The proceeds of the Offering will be used by Arch as general working capital and certain research expenses that are not covered by the Company's existing funding grants. The Offering is expected to close on or before July 31, 2024 and is subject to certain conditions including, but not limited to, the receipt of applicable regulatory approvals, including conditional and final approval of the TSX Venture Exchange, as well as the satisfaction of other customary closing conditions.

發行的收益將被Arch用作一般營運資本和某些研究開支,這些開支不被公司現有的資助資金所覆蓋。本次發行預計將於2024年7月31日或之前結束,並受某些條件的約束,包括但不限於獲得適用的監管批准,包括TSX Venture Exchange的有條件和最終批准,以及滿足其他慣例的結束條件。

All Common Shares issued in connection with the Offering will be subject to a hold period of four months and one day from the closing date. There are no finders' fees in connection with the Offering.

本次定向增發的所有普通股將受到四個月零一天的持有期限制,自交割日起計算。本次增發無需支付發現人費用。

There is no material fact or material change about the Company that has not been generally disclosed.

公司目前無任何未公開披露的重大事項或重大變化。

About Arch Biopartners

關於Arch Biopartners

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing inflammation and acute organ injury. The Company is developing a platform of new drugs to prevent inflammation in the kidneys, liver and lungs via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem.

Arch Biopartners Inc.是一家專注於預防炎症和急性器官損傷的晚期臨床試驗公司。該公司正在開發一系列通過二肽酶-1(DPEP1)途徑防止腎臟、肝臟和肺部炎症的新藥物平台,並與許多常見損傷和疾病相關,其中器官炎症是一個未被滿足的問題。

For more information on Arch Biopartners' science and drug platform, please visit:

欲了解更多Arch Biopartners的科學和藥物平台信息,請訪問:

For investor information and other public documents the company has also filed on SEDAR+, please visit

欲了解有關Arch Biopartners的投資者信息和公司在SEDAR+上提交的其他公共文件,請訪問

The Company has 64,250,633 common shares outstanding.

該公司擁有64,250,633股普通股。

Forward-Looking Statements

前瞻性聲明

This press release contains forward-looking statements within the meaning of applicable Canadian securities laws regarding expectations of our future performance, liquidity and capital resources, as well as the ongoing clinical development of our drug candidates targeting the dipeptidase-1 (DPEP1) pathway, including the outcome of our clinical trials relating to LSALT peptide (Metablok) or cilastatin, the successful commercialization and marketing of our drug candidates, whether we will receive, and the timing and costs of obtaining, regulatory approvals in Canada, the United States, Europe and other countries, our ability to raise capital to fund our business plans, the efficacy of our drug candidates compared to the drug candidates developed by our competitors, our ability to retain and attract key management personnel, and the breadth of, and our ability to protect, our intellectual property portfolio. These statements are based on management's current expectations and beliefs, including certain factors and assumptions, as described in our most recent annual audited financial statements and related management discussion and analysis under the heading "Business Risks and Uncertainties". As a result of these risks and uncertainties, or other unknown risks and uncertainties, our actual results may differ materially from those contained in any forward-looking statements. The words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We undertake no obligation to update forward-looking statements, except as required by law. Additional information relating to Arch Biopartners Inc., including our most recent annual audited financial statements, is available by accessing the Canadian Securities Administrators' System for Electronic Document Analysis and Retrieval ("SEDAR") website at .

本新聞稿包含根據適用的加拿大證券法的前瞻性聲明,涉及我們未來業績,流動性和資本資源的預期,以及針對二肽酶-1(DPEP1)途徑的我們藥物候選品的持續臨床開發,包括與LSALT肽(Metablok)或cilastatin相關的我們的臨床試驗的結果,我們藥物候選品的成功商業化和營銷,無論我們是否將在加拿大,美國,歐洲和其他國家獲得,以及獲得監管批准的時間和費用,我們籌集資金以資助我們的業務計劃,我們的藥物候選品與競爭對手開發的藥物候選品的功效相比,我們的關鍵管理人員保留和吸引的能力,以及我們知識產權組合的廣度和保護能力。 這些陳述基於管理層的當前期望和信念,包括某些因素和假設,如我們最近的年度審計財務報表以及相關管理討論和分析中在“業務風險和不確定性”標題下所述。 由於這些風險和不確定性,或其他未知的風險和不確定性,我們的實際結果可能與任何前瞻性聲明中所包含的結果有所不同。 雖然並非所有前瞻性聲明都包含這些識別詞,但“相信”,“可能”,“計劃”,“將”,“估計”,“繼續”,“預期”和類似用語旨在識別前瞻性聲明。 我們未承擔更新前瞻性聲明的義務,除非法律要求。 有關Arch Biopartners Inc.的其他信息,包括我們最近的年度審計財務報表,請訪問加拿大證券管理機構的電子文件分析和檢索系統(“SEDAR”)網站。

The science and medical contents of this release have been approved by the Company's Chief Science Officer

本發佈稿的科學和醫學內容已獲公司首席科學官批准

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

TSX Venture Exchange及其監管服務提供者(如TSX Venture Exchange的政策中所定義的)不接受對本發佈內容的充分性或準確性的責任。

CONTACT: For more information, please contact:

Richard Muruve
Chief Executive Officer
Arch Biopartners, Inc.
647-428-7031
info@archbiopartners.com
聯繫人:了解更多信息,請聯繫:

Richard Muruve
首席執行官
Arch Biopartners, Inc.
647-428-7031
info@archbiopartners.com

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論